Form 4: Sage Therapeutics Director Disposes Options Following Supernus Merger Completion

A director of Sage Therapeutics, Michael F. Cola, disposed of stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Summary

• Sage Therapeutics, Inc. completed its merger with Supernus Pharmaceuticals, Inc. and its subsidiary Saphire, Inc., effective July 31, 2025.
• The merger involved a cash tender offer to purchase all outstanding shares of Sage Therapeutics common stock.
• Shareholders received $8.50 per share in cash (the 'Closing Amount') plus one contingent value right (CVR) per share.
• Each CVR represents the right to receive up to an additional $3.50 per share in cash upon the satisfaction of specified milestones.
• Michael F. Cola, a director of Sage Therapeutics, disposed of 21,500 stock options with an exercise price of $6.77 per share.
• These options were deemed fully vested, cancelled, and converted into a cash payment of $37,195.00 (calculated as ($8.50 $6.77) * 21,500 shares) and 21,500 CVRs.
• Any Company Options with an exercise price greater than or equal to the Closing Amount ($8.50) were cancelled without consideration.

Sentiment

Score: 8

Explanation: The sentiment is positive as the merger successfully closed, providing immediate cash value to shareholders and option holders for in-the-money options, along with potential future upside via CVRs. The disposition of options is a standard procedural outcome of such an event.

Positives

• The merger of Sage Therapeutics with Supernus Pharmaceuticals, Inc. has been successfully completed.
• In-the-money stock options held by insiders, such as Michael F. Cola, were converted into cash and contingent value rights, providing immediate liquidity and potential future upside.
• Shareholders received a fixed cash payment of $8.50 per share at closing, providing certainty of value.

Negatives

• Stock options with an exercise price equal to or greater than the $8.50 Closing Amount were cancelled without any consideration, resulting in a loss of value for holders of those options.
• The full value of the contingent value rights (up to $3.50 per share) is dependent on the achievement of future milestones, introducing an element of uncertainty.

Risks

• The value of the contingent value rights (CVRs) is not guaranteed and depends entirely on the satisfaction of specified milestones, which may or may not be achieved.
• There is no further upside for common shareholders beyond the $8.50 cash payment and the potential CVR value, as Sage Therapeutics is no longer an independent publicly traded entity.

Future Outlook

The future outlook for the contingent value rights (CVRs) is dependent on the satisfaction of specified milestones, which could result in an additional cash payment of up to $3.50 per share.

Management Comments

• The Agreement and Plan of Merger, dated June 13, 2025, outlines the terms under which Supernus Pharmaceuticals, Inc. acquired Sage Therapeutics, Inc.
• The merger consideration included a cash payment of $8.50 per share and one contingent value right per share, reflecting the agreed-upon value for Sage Therapeutics' equity.

Industry Context

This transaction represents a strategic acquisition within the pharmaceutical and biotechnology sector, where larger companies often acquire smaller, specialized firms to expand their product pipelines or market presence. The use of contingent value rights is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash and contingent value rights for their shares, realizing value from their investment.
• Employees holding stock options were impacted, with in-the-money options converted to cash and CVRs, while out-of-the-money options were cancelled.
• The merger signifies a change in ownership and strategic direction for the company, potentially impacting employees, customers, and suppliers as operations integrate with Supernus Pharmaceuticals.

Next Steps

• Achievement of specified milestones for the contingent value rights to trigger additional cash payments.

Key Dates

Keywords

Sage Therapeutics, SAGE, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, Tender Offer, Corporate Governance